Role of antiplatelet therapy in cardiovascular disease I: acute coronary syndromes
Authors: Jeffrey J. Cavendish1; Randolph V. Fugit2; Michael Safani3
Source: Current Medical Research and Opinion, Volume 20, Number 11, November 2004 , pp. 1839-1843(5)
Publisher: Informa Healthcare
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Abstract:
The acute coronary syndromes (ACS), consisting of ST-segment elevation myocardial infarction (STEMI), non-STEMI (NSTEMI), and unstable angina, remain a leading cause of death in the United States. Through the process of atherothrombosis, underlying atherosclerosis can progress to an acute ischemic coronary event. This disease mechanism is also common to ischemic stroke and peripheral arterial disease. As ACS is a heterogeneous disease, accurate patient diagnosis and risk categorization is essential. Treatment approaches for both STEMI and NSTEMI ACS consist of a combination of surgical intervention and pharmacotherapy, with antiplatelet agents such as clopidogrel, aspirin and glycoprotein IIb/IIIa receptor antagonists playing an essential role.Keywords: ACUTE CORONARY SYNDROMES; ANTIPLATELET; ATHEROTHROMBOSIS; MYOCARDIAL INFARCTION; UNSTABLE ANGINA
Document Type: Research article
DOI: 10.1185/030079904X10665
Affiliations: 1: Department of Cardiology, Naval Medical Center, San Diego, CA, USA 2: Department of Pharmacy, Denver Veterans Affairs Medical Center, Denver, USA 3: Long Beach Memorial Medical Center, CA and Volunteer Faculty, University of California in San Francisco, Redondo Beach, CA, USA
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Click here for Page Help